drugset / Trial / NCT00002902

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

NCT00002902

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.

Timeline

Start
1997-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule Intravenous
Subject Raltitrexed Small molecule Intravenous